Diffusion Pharmaceuticals LLCMedia:David G. Kalergis, MBA/JDCEO434-220-0718orGBM Study Information:Kim Whitten, Pharm.D,Vice President, Drug Development434-220-0718 Diffusion Pharmaceuticals LLC, a ...
Diffusion Pharmaceuticals announced that trans sodium crocetinate (TSC) has been granted an Orphan Drug designation by the FDA for the treatment of metastatic brain cancer. TSC is a proprietary, first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results